Hydrus Microstent Articles & Analysis: Older
9 news found
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% ...
About Hydrus Microstent Roughly the size of an eyelash, the Hydrus Microstent is a next-generation MIGS device designed to reduce eye pressure by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. ...
” More Evidence for Hydrus Microstent Than for Any Other MIGS Device The duration of follow-up on the Hydrus Microstent, combined with the quantity of top-tier published evidence, sets the Hydrus Microstent apart from other MIGS devices. There are currently five publications about the ...
” To learn more, visit Ivantisinc.com. About Hydrus Microstent Roughly the size of an eyelash, the Hydrus Microstent is a next-generation MIGS device designed to reduce eye pressure by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. When placed in the canal during minimally ...
This is the fifth peer-reviewed article on the Hydrus Microstent to be published in the industry’s preeminent journal. ...
Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone. The two-year results of the trial provided the foundation for FDA approval of the Hydrus Microstent. ...
SPECTRUM is a post market patient registry for the Hydrus® Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with open-angle glaucoma in conjunction with cataract surgery or as a stand-alone procedure outside the United States. ...
Over the last year since FDA approval, we have been extremely pleased by the strong reception of our Hydrus Microstent by the clinical community, and our long-term clinical data has been an important driver for this adoption.” About the Hydrus® Microstent Roughly the size of an eyelash, the Hydrus® ...